Aclaris Therapeutics (ACRS) Equity Average (2015 - 2026)

Aclaris Therapeutics' Equity Average history runs 12 years deep, the most recent figure standing at $123.4 million for Q1 2026.

• In Q1 2026, Equity Average fell 17.65% year-over-year to $123.4 million; the TTM figure through Mar 2026 stood at $123.4 million (down 17.65% YoY), while the FY2025 annual figure was $129.3 million, down 17.3% from the prior year.
• Equity Average was $123.4 million for Q1 2026 at Aclaris Therapeutics, up from $111.6 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $227.8 million in Q3 2022 to a low of $111.6 million in Q4 2025.
• Historically, Equity Average has averaged $160.9 million across 5 years, with a median of $149.8 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Equity Average jumped 151.79% in 2022, then declined 26.23% in 2023.
• A 5-year view of Equity Average shows it stood at $208.7 million in 2022, then decreased by 24.9% to $156.8 million in 2023, then fell by 8.87% to $142.9 million in 2024, then slipped by 21.88% to $111.6 million in 2025, then increased by 10.55% to $123.4 million in 2026.
• The last three Equity Average figures came in at $123.4 million (Q1 2026), $111.6 million (Q4 2025), and $125.9 million (Q3 2025), per Business Quant data.